Key result
Prasugrel and ticagrelor showed no significant difference in mortality (OR 1.52) or other adverse cardiovascular outcomes in patients with acute coronary syndrome.
Why the study?
Does prasugrel reduce adverse cardiovascular outcomes compared to ticagrelor in patients with acute coronary syndrome?
Population
563 patients with acute coronary syndrome (ACS) pooled from 4 randomized trials
Comparison
Prasugrel vs Ticagrelor
Design
Meta-analysis
Authors
Loading...
No superiority between prasugrel and ticagrelor in ACS; reinforces guideline equipoise for either agent.
Meta-Analysis (n=563)
Does prasugrel reduce adverse cardiovascular outcomes compared to ticagrelor in patients with acute coronary syndrome?
Odds Ratio: 1.52 (95% CI 0.42–5.45)
p-value: p=0.52
In a meta-analysis of 563 patients with ACS, direct head-to-head comparison of prasugrel and ticagrelor showed no significant differences in adverse cardiovascular outcomes or bleeding events.
Bundhun et al. (2017) conducted a meta-analysis in Acute coronary syndrome (n=563). Prasugrel vs. Ticagrelor was evaluated on Mortality (OR 1.52, 95% CI 0.42-5.45, p=0.52). Prasugrel and ticagrelor showed no significant difference in mortality (OR 1.52) or other adverse cardiovascular outcomes in patients with acute coronary syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: